carbimazole Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Carbimazole (brand names Neo-Mercazole, Anti-Thyrox, etc.) is used to treat hyperthyroidism. Carbimazole is a pro-drug as after absorption it is converted to the active form, methimazole. Methimazole prevents thyroid peroxidase enzyme from iodinating and coupling the tyrosine residues on thyroglobulin, hence reducing the production of the thyroid hormones T3 and T4 (thyroxine).   Wikipedia

Chemistry

  • SMILES: CCOC(=O)n1ccn(C)c1=S
  • InChIKey: CFOYWRHIYXMDOT-UHFFFAOYSA-N
  • Mol. Mass: 186.24
  • ALogP: 1.56
  • ChEMBL Molecule:
    carbimazole  
More Chemistry

Pharmacology

Drug Pricing (per unit)

Australia

$0.1069
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

1h-imidazole-1-carboxylic acid, 2,3-dihydro-3-methyl-2-thioxo-, ethyl ester ethyl 3-methyl-2-thioimidazoline-1-carboxylate | athyromazole | carbethoxymethimazole | carbimazol | carbimazole | carbimazolo | carbimazolum | carbinazole | ethyl 3-methyl-2-thioimidazoline-1-carboxylate | neomercazole | neo-mercazole 20 | neo-mercazole 5

Organizations (8)

Research & Development (8)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (1)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (1)


 

Pediatrics (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial Organizations: 8

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue